You are here

Novartis

Novartis gets FDA nod for advanced breast-cancer treatment

Novartis gets FDA nod for advanced breast-cancer treatment

Marketwatch

advanced breast cancer

Flag link:

Novartis on goal to hit mid-30s margins by 2022

Novartis on goal to hit mid-30s margins by 2022

BioCentury

Flag link:

Novartis gene therapy approved, but will come at cost of more than $2 million

Novartis gene therapy approved, but will come at cost of more than $2 million

Biopharma Dive

Flag link:

Novartis’ inhaled asthma combo QVM149 succeeds in two phase 2 trials

Novartis’ inhaled asthma combo QVM149 succeeds in two phase 2 trials

Pharmaceutical Business Review

clinical trials

Flag link:

Novartis chief Vas Narasimhan wants you to know about the '25-plus’ blockbusters he has in the pipeline

Novartis chief Vas Narasimhan wants you to know about the '25-plus’ blockbusters he has in the pipeline

Endpoints

Flag link:

Novartis CEO plans gene therapy price 'far lower' than $4 million to $5 million range

Novartis CEO plans gene therapy price 'far lower' than $4 million to $5 million range

Yahoo/Reuters

Flag link:

Novartis' asthma triplet beats GSK's Advair in phase 2 trial

Novartis' asthma triplet beats GSK's Advair in phase 2 trial

Fierce Pharma

clinical trials

Flag link:

Verily lures major pharmas with promise of speedier clinical research

Verily lures major pharmas with promise of speedier clinical research

BioPharma Dive

clinical trials

Flag link:

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

Yahoo/Benzinga

Bellerophon Therapeutics

Bicycle Therapeutics

Peloton Therapeutics

Flag link:

GSK and Novartis liniment marketing misled Australian consumers: court

GSK and Novartis liniment marketing misled Australian consumers: court

Reuters

Flag link:

Upcoming events – Phase III data for Chiasma and Novartis

Upcoming events – Phase III data for Chiasma and Novartis

EP Vantage

clinical trials

multiple sclerosis

Flag link:

Commentary: Novartis CEO: Gene therapy offers hope of cures in one treatment, but US needs new pricing and payment model

Commentary: Novartis CEO: Gene therapy offers hope of cures in one treatment, but US needs new pricing and payment model

CNBC

Flag link:

Alcon Beats Expectations Since its Split from Novartis

Alcon Beats Expectations Since its Split from Novartis

Medical Devices and Diagnostics Industry

Flag link:

Better than CAR-T? Already prepping for a US launch, MorphoSys posts stellar DLBCL data to field against Novartis, Gilead

Better than CAR-T? Already prepping for a US launch, MorphoSys posts stellar DLBCL data to field against Novartis, Gilead

Endpoints

Gilead Sciences

Flag link:

Novartis takes another step forward in global Kymriah rollout as Japan OKs the drug at $305K

Novartis takes another step forward in global Kymriah rollout as Japan OKs the drug at $305K

Endpoints

Flag link:

Novartis' Sandoz does digital from back office to 'not just apps' therapeutics

Novartis' Sandoz does digital from back office to 'not just apps' therapeutics

Fierce Pharma

Flag link:

Novartis’ Gilenya proves superiority over glatiramer acetate in relapsing remitting MS

Novartis’ Gilenya proves superiority over glatiramer acetate in relapsing remitting MS

Pharmaceutical Business Review

Relapsing Remitting Multiple Sclerosis

Flag link:

Novartis vows to fight U.S. price-fixing claims against Sandoz unit

Novartis vows to fight U.S. price-fixing claims against Sandoz unit

Yahoo/Reuters

Flag link:

Takeda sells Shire’s Xiidra, transfers 400 staffers to Novartis in $3.4B deal

Takeda sells Shire’s Xiidra, transfers 400 staffers to Novartis in $3.4B deal

Fierce Pharma

dry eye disease

Flag link:

Novartis sees Saudi Arabia as promising market for producing its cancer drugs

Novartis sees Saudi Arabia as promising market for producing its cancer drugs

Fierce Pharma

Flag link:

Pages